Adherium Ltd (ASX: ADR) Share Price and News

Mr Panaccio is a Non-executive Director of Unison Housing Limited, VGI Health Technology Limited, NeuralDX Limited and Haemokinesis Limited. Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology, the Chief Executive Officer of Monash IVF and the Executive Chairman of Health Networks Australia.

Dr Hunter has experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals and assumed the position of CEO when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor. He is currently President and CEO of Canary Medical Inc. and formerly Correvio Pharma Corp. Dr Hunter is also a Director of Rex Bionics and an Industry Expert Advisor for BioScience Managers. He has previously served as a director of Epirus Biopharmaceuticals and Union Medtech.

Mr McHarrie is a company director and adviser in the health and life sciences sectors with over 25 years' experience. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early-stage biotechnology and healthcare companies.

Mr Curnock Cook was head of the life science private equity team at Rothschild Asset Management in the UK and is an active investor in the Australian life science sector. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through active participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, AMEX, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers, and sits on the board of Avita Medical, Rex Bionics Pty, Humanetix Ltd, Marine Department Ltd, Cambridge Respiratory Innovations Ltd, and Sea Dragon Ltd. Mr Curnock Cook was previously a director of Bioxyne Limited and Phylogica Limited.

Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a significant shareholder. In addition to his role at Trudell, Mr Baran is an active investor in and Director of several medical device and e-health/connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. He was also a lead investor and a former Director of Vanrx Phamasystems, which was recently acquired by Cytiva Life Sciences.

-

-

-

-

-

-

-

-